by Mickael Marsali | Sep 8, 2016
In one of the most common forms of cancer immunotherapy, scientists inject foreign substances into the body to elicit immune responses at tumor sites. Unfortunately, this type of immunotherapy has only generated limited results in the past. On top of this obstacle,...
by Mickael Marsali | Sep 3, 2016
Novan, a biotech company focused on dermatology, has recently lowered its IPO to $45 million. Given the difficulty smaller biotechs have encountered this year, Novan should perhaps consider itself lucky that it is even able to go for an IPO. After all, a considerable...
by Mickael Marsali | Jul 25, 2016
Imagine being handed puzzle to solve that’s made up of literally millions of tiny pieces. Maybe you would sit down and start with the corners, work your way across the edges, and then start piecing together the middle based on like-colors. Now imagine that as...
by Mickael Marsali | Jun 23, 2016
CRISPR (i.e. clustered regularly interspaced short palindromic repeat), a segment of gene editing treatment that is thought to be one of the cutting edge developments in genetic engineering, is finally approaching clinical trials to be used on humans. Many are hopeful...
by Mickael Marsali | Jun 20, 2016
MIT Technology Review had some interesting news to break today: the first proposed test of CRISPR gene-editing technology in human beings is being funded by none other than Internet billionaire Sean Parker, the well-known cofounder behind Napster and first president...
Biotech News